Biologics‑
PET

Our focus

The studies in workpackage 4 (WP4) will focus on the use of imaging of the in vivo distribution and target interaction of biologics with positron emission tomography (PET), fluorescence imaging and mass spectrometry imaging (MSI) to obtain insight in the safety, efficacy and side-effects of new biologics in the early stage of the drug development process. To use these techniques for this specific purpose, members of WP4 will develop and test labelling agents to label biologics with 89Zr and fluoreophores. The labelled biologics will be studied to elucidate those aspects of the biodistribution and interaction with the target tissue to assess the safety and clinical translation of novel biologics. The studies In WP4 will include in vitro studies, preclinical studies in animal models and clinical studies.

The key objectives

  1. Develop and evaluate new methods to label biologics with 89Zr.
  2. Demonstrate whether advanced imaging techniques are able to identify characteristics of new biologics important for evaluation of the safety and clinical translation.
  3. Investigate the possibilities to monitor therapeutic function of novel biologics by PET imaging.

Imaging methods and tracer development

  • 89Zr labelling
  • PET Imaging
  • Fluorescent Imaging
  • MS Imaging

Imaging studies animal models

  • 89Zr labelled biologics
  • 18F labelled biologics
  • Fluorescent labelled biologics

Clinical imaging studies

  • 89Zr labelled biologics
  • 18F labelled biologics

Our Partners for biologics-PET

Slide
Slide
Slide
Slide
Slide
Slide
Slide

Publications

Conference Abstract: Novel 89Zr chelator

13.10.2018

Evaluation of the in vitro and in vivo characteristics of the novel89Zr-octacoordinated chelator DFO-cyclo* compared to the hexacoordinated DFO

Read more

Conference Abstract: IL-2 PET

13.10.2018

Development and evaluation of a new Interleukin-2 PET radioligand Al[18F]RESCA-IL2: comparison with [18F]FB-IL2

Read more

Conference Abstract: 89Zr chelate evaluation

26.09.2018

In vitro and in vivo evaluation of novel 89Zr-chelators

Read more

Conference Abstract: DFO-cyclo versus DFO

05.04.2018

In vitro and in vivo comparison of the novel 89Zr chelator DFO-cyclo* with DFO

Read more

89Zr Radiochemistry Review

24.08.2017

89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.

Read more